tirzepatide jamaica Lilly's reduces type 2 diabetes risk, shows weight loss SURPASS-CVOT Published: Large Trial Confirms

During the subsequent 17-week off-treatment period, the patients began to regain weight and showed some increases in type 2 diabetes progression, resulting in a 88% diabetes risk reduction after the off-period

One major Wall Street investment firm says some sugary drink brands will survive this health trend

Reduced appetite is the intended effect, though it sometimes feels too extreme

This article explores common reasons for suboptimal response, clarifies realistic timelines for therapeutic effect, and identifies when medical consultation is necessary to optimize treatment outcomes or consider alternative approaches

Mounjaro FDA Approval History Last updated by Judith Stewart, BPharm on Feb 10, 2026

The magnitude of effect was also consistent in SURPASS 4 which enrolled patients with established cardiovascular disease